76
|
Barry WT, Perou CM, Marcom PK, Carey LA, Ibrahim JG. The use of Bayesian hierarchical models for adaptive randomization in biomarker-driven phase II studies. J Biopharm Stat 2015; 25:66-88. [PMID: 24836519 DOI: 10.1080/10543406.2014.919933] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
The role of biomarkers has increased in cancer clinical trials such that novel designs are needed to efficiently answer questions of both drug effects and biomarker performance. We advocate Bayesian hierarchical models for response-adaptive randomized phase II studies integrating single or multiple biomarkers. Prior selection allows one to control a gradual and seamless transition from randomized-blocks to marker-enrichment during the trial. Adaptive randomization is an efficient design for evaluating treatment efficacy within biomarker subgroups, with less variable final sample sizes when compared to nested staged designs. Inference based on the Bayesian hierarchical model also has improved performance in identifying the sub-population where therapeutics are effective over independent analyses done within each biomarker subgroup.
Collapse
|
77
|
Lin NU, Guo H, Yap JT, Mayer IA, Falkson CI, Hobday TJ, Dees EC, Richardson AL, Nanda R, Rimawi MF, Ryabin N, Najita JS, Barry WT, Arteaga CL, Wolff AC, Krop IE, Winer EP, Van den Abbeele AD. Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003). J Clin Oncol 2015; 33:2623-31. [PMID: 26169615 DOI: 10.1200/jco.2014.60.0353] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
PURPOSE Lapatinib plus trastuzumab improves outcomes relative to lapatinib alone in heavily pretreated, human epidermal growth factor receptor 2-positive metastatic breast cancer (MBC). We tested the combination in the earlier-line setting and explored the predictive value of [(18)F]fluorodeoxyglucose positron emission tomography ([(18)F]FDG-PET) for clinical outcomes. PATIENTS AND METHODS Two cohorts were enrolled (cohort 1: no prior trastuzumab for MBC and ≥ 1 year from adjuvant trastuzumab, if given; cohort 2: one to two lines of chemotherapy including trastuzumab for MBC and/or recurrence < 1 year from adjuvant trastuzumab). The primary end point was objective response rate by RECIST v1.0; secondary end points included clinical benefit rate (complete response plus partial response plus stable disease ≥ 24 weeks) and progression-free survival. [(18)F]FDG-PET scans were acquired at baseline, week 1, and week 8. Associations between metabolic response and clinical outcomes were explored. RESULTS Eighty-seven patients were registered (85 were evaluable for efficacy). The confirmed objective response rate was 50.0% (95% CI, 33.8% to 66.2%) in cohort 1 and 22.2% (95% CI, 11.3% to 37.3%) in cohort 2. Clinical benefit rate was 57.5% (95% CI, 40.9% to 73.0%) in cohort 1 and 40.0% (95% CI, 25.7% to 55.7%) in cohort 2. Median progression-free survival was 7.4 and 5.3 months, respectively. Lack of week-1 [(18)F]FDG-PET/computed tomography ([(18)F]FDG-PET/CT) response was associated with failure to achieve an objective response by RECIST (negative predictive value, 91% [95% CI, 74% to 100%] for cohort 1 and 91% [95% CI, 79% to 100%] for cohort 2). CONCLUSION Early use of lapatinib and trastuzumab is active in human epidermal growth factor receptor 2-positive MBC. Week-1 [(18)F]FDG-PET/CT may allow selection of patients who can be treated with targeted regimens and spared the toxicity of chemotherapy.
Collapse
|
78
|
Ligibel JA, Cirrincione CT, Liu M, Citron M, Ingle JN, Gradishar W, Martino S, Sikov W, Michaelson R, Mardis E, Perou CM, Ellis M, Winer E, Hudis CA, Berry D, Barry WT. Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance). J Natl Cancer Inst 2015; 107:djv179. [PMID: 26113580 DOI: 10.1093/jnci/djv179] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2015] [Accepted: 06/02/2015] [Indexed: 01/12/2023] Open
Abstract
BACKGROUND Obesity at diagnosis is associated with poor prognosis in women with breast cancer, but few reports have been adjusted for treatment factors. METHODS CALGB 9741 was a randomized trial of dose density and sequence of chemotherapy for node-positive breast cancer. All patients received doxorubicin, cyclophosphamide, and paclitaxel, dosed by actual body weight. Height and weight at diagnosis were abstracted from patient records, and the PAM50 assay was performed from archived specimens using the NanoString platform. Relationships between body mass index (BMI), PAM50, and recurrence-free and overall survival (RFS and OS) were evaluated using proportional hazards regression, adjusting for number of involved nodes, estrogen receptor (ER) status, tumor size, menopausal status, drug sequence, and dose density. All statistical tests were two-sided. RESULTS Baseline height and weight were available for 1909 of 2005 enrolled patients; 1272 additionally had subtype determination by PAM50. Median baseline BMI was 27.4kg/m(2). After 11 years of median follow-up, there were 619 RFS events and 543 deaths. Baseline BMI was a statistically significant predictor of RFS (adjusted hazard ratio [HR] for each five-unit increase in BMI = 1.08, 95% confidence interval [CI] = 1.02 to 1.14, P = .01) and OS (adjusted HR = 1.08, 95% CI = 1.01 to 1.14, P = .02) BMI and molecular phenotypes were independent prognostic factors for RFS, with no statistically significant interactions detected. CONCLUSIONS BMI at diagnosis was a statistically significant prognostic factor in a group of patients receiving optimally dosed chemotherapy. Additional research is needed to determine the impact of weight loss on breast cancer outcomes and to evaluate whether this impact is maintained across tumor subtypes.
Collapse
|
79
|
Rugo HS, Barry WT, Moreno-Aspitia A, Lyss AP, Cirrincione C, Leung E, Mayer EL, Naughton M, Toppmeyer D, Carey LA, Perez EA, Hudis C, Winer EP. Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance). J Clin Oncol 2015; 33:2361-9. [PMID: 26056183 DOI: 10.1200/jco.2014.59.5298] [Citation(s) in RCA: 155] [Impact Index Per Article: 17.2] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE We compared nab-paclitaxel or ixabepilone once per week to paclitaxel with bevacizumab as first-line therapy for patients with advanced breast cancer (BC) to evaluate progression-free survival (PFS) for nab-paclitaxel or ixabepilone versus paclitaxel. PATIENTS AND METHODS Eligible patients were age ≥ 18 years with chemotherapy-naive advanced BC. Patients were randomly assigned to bevacizumab with paclitaxel 90 mg/m(2) (arm A), nab-paclitaxel 150 mg/m(2) (arm B), or ixabepilone 16 mg/m(2) (arm C), once per week for 3 of 4 weeks. Planned enrollment was 900 patients, which would give 88% power to detect a hazard ratio of 0.73. RESULTS In all, 799 patients were enrolled, and 783 received treatment (97% received bevacizumab). Arm C was closed for futility at the first interim analysis (n = 241), and arm A (n = 267) and arm B (n = 275) were closed for futility at the second interim analysis. Median PFS for paclitaxel was 11 months, ixabepilone was inferior to paclitaxel (PFS, 7.4 months; hazard ratio, 1.59; 95% CI, 1.31 to 1.93; P < .001), and nab-paclitaxel was not superior to paclitaxel (PFS, 9.3 months; hazard ratio, 1.20; 95% CI, 1.00 to 1.45; P = .054). Results were concordant with overall survival; time to treatment failure was significantly shorter in both experimental arms v paclitaxel. Hematologic and nonhematologic toxicity, including peripheral neuropathy, was increased with nab-paclitaxel, with more frequent and earlier dose reductions. CONCLUSION In patients with chemotherapy-naive advanced BC, ixabepilone once per week was inferior to paclitaxel, and nab-paclitaxel was not superior with a trend toward inferiority. Toxicity was increased in the experimental arms, particularly for nab-paclitaxel. Paclitaxel once per week remains the preferred palliative chemotherapy in this setting.
Collapse
|
80
|
Vaz-Luis I, Lin NU, Keating NL, Barry WT, Lii H, Winer EP, Freedman RA. Racial differences in outcomes for patients with metastatic breast cancer by disease subtype. Breast Cancer Res Treat 2015; 151:697-707. [DOI: 10.1007/s10549-015-3432-1] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2015] [Accepted: 05/18/2015] [Indexed: 12/26/2022]
|
81
|
Richardson AL, Silver DP, Szallasi Z, Birkbak NJ, Wang ZC, Iglehart JD, Mayer EL, Winer EP, Tung NM, Ryan PD, Isakoff SJ, Barry WT, Greene-Collozi A, Gutin A, Reid J, Neff C, Jones J, Timms K, Hartman AR, Garber JE. Abstract P3-06-11: Homologous recombination deficiency (HRD) assay predicts response to cisplatin neoadjuvant chemotherapy in patients with triple negative breast cancer. Cancer Res 2015. [DOI: 10.1158/1538-7445.sabcs14-p3-06-11] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
A significant proportion of triple negative breast cancers (TNBC) carry defects in DNA repair including Homologous Recombination (HR) defects and are sensitive to therapies that target these pathways. Several clinical trials have demonstrated improvement in pathologic response with the addition of platinum to standard of care neoadjuvant regimens but at a cost of increased toxicities. Recently three DNA based metrics (LOH, Abkevich et al. 2012 Br J Cancer; TAI, Birkbak et al. 2012 Cancer Discov; LST, Popava et al. 2012 Cancer Res) have been developed, shown to be highly associated with BRCA1/2 mutation status, and found to predict sensitivity to platinum based chemotherapy in TNBC. The HRD Score was defined as the sum of LOH, TAI, and LST measurements, and a threshold separating tumors with high and low HRD Scores was established. This study assesses the association of HRD Score with response to cisplatin neoadjuvant chemotherapy in patients with TNBC. A clinical test that identifies tumors with defects in HR may distinguish those patients more likely to benefit from the addition of platinum.
Methods: Archival tumor samples were obtained from 74 patients with TNBC from 2 separate clinical trials conducted at DFHCC under IRB approved protocols. One trial enrolled 28 patients who received neoadjuvant cisplatin monotherapy (Silver et al., 2010 J Clin Oncol). The second trial enrolled 51 patients who received cisplatin and bevacizumab chemotherapy (Ryan, et al.,2009 J Clin Oncol). HRD Score and tumor BRCA1/2 mutation status were determined. BRCA1/2 deficiency was defined as the presence of BRCA1/2 mutation with loss of the second allele in the tumor. Response was categorized by the residual cancer burden (RCB) score with responders defined as RCB0 or 1, and non-responders as RBC2 or 3. A second measure of response, pathologic complete response (pCR), was defined as RCB0 and non-responders as RCB1,2 or 3. Logistic regression was used to evaluate HRD Score in combination with BRCA1/2 deficiency as a predictor of response to neoadjuvant therapy. All analysis was conducted according to a pre-specified Statistical Analysis Plan.
Results: As of May 29, 2014 41 samples have been processed. Seven carried deleterious mutations in BRCA1/2 (17%). Thirty-three of the tumors produced SNP data of sufficient quality for HRD score calculation. HRD scores in the passing samples ranged from 7 – 74, with an average score of 45. The HRD scores observed in BRCA1/2 mutation carriers (n=6) ranged from 43 – 57 with an average HRD score of 55. We anticipate that all molecular data will be generated by July 1, 2014. Correlation with pCR and RCB0/1 will be assessed.
Conclusions: The LOH, TAI, and LST metrics have been shown in previous studies to predict response to platinum-based neoadjuvant chemotherapy in patients with TNBC. This study will be a validation of LOH, TAI and LST in the form of a combined score, and will demonstrate that HRD Score can be used as a tool to identify patients with breast tumors with underlying HR deficiency who may benefit from platinum therapy.
Citation Format: Andrea L Richardson, Daniel P Silver, Zoltan Szallasi, Nicolai J Birkbak, Zhigang C Wang, J Dirk Iglehart, Erica L Mayer, Eric P Winer, Nadine M Tung, Paula D Ryan, Steven J Isakoff, William T Barry, April Greene-Collozi, Alexander Gutin, Julia Reid, Chris Neff, Joshua Jones, Kirsten Timms, Anne-Renee Hartman, Judy E Garber. Homologous recombination deficiency (HRD) assay predicts response to cisplatin neoadjuvant chemotherapy in patients with triple negative breast cancer [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P3-06-11.
Collapse
|
82
|
Jeselsohn RM, Barry WT, Zhao J, Buchwalter G, Guarducci C, Migliaccio I, Biagioni C, Bonechi M, Laing N, Rukazenkov Y, Winer EP, Brown M, Di Leo A, Malorni L. Abstract S1-01: TransCONFIRM: The correlative analysis of breast tumors from patients with advanced hormone receptor positive disease identifies a genetic signature associated with decreased benefit from single agent fulvestrant. Cancer Res 2015. [DOI: 10.1158/1538-7445.sabcs14-s1-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Several multi-gene expression based assays have been developed to assess the prognosis and predict response to endocrine treatments in early stage hormone receptor positive (HR+) breast cancer. Although a significant number of patients with metastatic ER+ disease will not respond to endocrine treatments, molecular assays to predict response in this setting are limited. In addition, tissue specimens of metastatic lesions for molecular studies are not always available. In this study we sought to identify a molecular profile in the primary tumors of patients who developed disease recurrence that could predict response to endocrine treatment in metastatic disease.
Methods: We used the primary breast tumor samples from a subgroup of patients participating in the randomized phase III CONFIRM trial, which compared 500mg versus 250mg of fulvestrant in post-menopausal women with HR+ advanced breast cancer. Formalin- fixed paraffin embedded tumors were collected from 130 of the participants and were centrally reviewed for ER, PR, HER2 and Ki67. RNA was sufficient for gene expression profiling in 112 of the cases using the NuGEN Ovation FFPE WTA System and Affymetrix HTA 2.0 GeneChip. The majority of the patients in this analysis developed metastatic disease during adjuvant endocrine treatment (N=55) or had de-novo metastatic disease (N=39) versus relapse after adjuvant treatment (N=18). The association between gene expression and progression free survival (PFS) was investigated using a multivariate Cox proportional hazard model adjusting for statistically significant clinicopatholgical factors. In addition we performed pathway-level analysis and evaluated the PAM50 subtype predictor and Risk of Relapse (ROR) score.
Results: The median PFS was 8 months in our cohort. HER2 level by immunohistochemistry above 1+, high PR level, defined as Allred score of above 6, and Ki67 of above 50% were significantly associated with PFS and were included in the multivariate model. Dose of fulvestrant was not associated with PFS in this cohort. We identified a signature of 25 genes that is inversely associated with PFS on fulvestrant treatment (FDR 20%). When compared to other published datasets of breast cancer tumors, these genes are enriched in tumors with poor outcome and triple negative cancers. Pathway analysis revealed an association between activation of the EGFR pathway and decreased PFS (P=0.01). PAM50 subtypes varied with the luminal subtype being the most common (65%) and were generally concordant with the clinical subtype. However, we did not detect a significant trend between PAM50 subtype or ROR score and PFS or overall survival.
Conclusions: In this cohort of patients with early and de-novo metastatic disease we identified a gene signature in the primary tumors that is associated with decreased response to fulvestrant treatment in metastatic disease. This signature warrants further validation to determine it’s predictive value and potential to assist in treatment decision making for patients with HR+ metastatic disease.
Citation Format: Rinath M Jeselsohn, William T Barry, Jin Zhao, Gilles Buchwalter, Cristina Guarducci, Ilenia Migliaccio, Chiara Biagioni, Martina Bonechi, Naomi Laing, Yuri Rukazenkov, Eric P Winer, Myles Brown, Angelo Di Leo, Luca Malorni. TransCONFIRM: The correlative analysis of breast tumors from patients with advanced hormone receptor positive disease identifies a genetic signature associated with decreased benefit from single agent fulvestrant [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr S1-01.
Collapse
|
83
|
Iglesia MD, Vincent BG, Serody JS, Carey LA, Barry WT, Sikov WM, Hudis CA, Winer EM, Perou CM. Abstract PD1-2: Impact of tumor-infiltrating B-cell clonal diversity on response to neoadjuvant therapy in triple negative and HER2+ breast cancer treated on CALGB (Alliance) 40601 and 40603. Cancer Res 2015. [DOI: 10.1158/1538-7445.sabcs14-pd1-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Tumor infiltrating lymphocytes (TILs) are associated with improved outcomes in breast (BrCa) and ovarian cancer (OvCa). This benefit is largely restricted to the basal-like and HER2-enriched subtypes of BrCa and the immunoreactive subtype of OvCa. It is not known whether TILs respond to a small subset of antigens, similar to an antiviral or antibacterial response, or if the response is nonspecific. We developed a novel method to assess B-cell population diversity by analyzing B-cell receptor (BCR) sequence complexity in mRNA-seq datasets derived from tumor biopsies. B-cells in a subset of basal-like and HER2-enriched BrCa showed high expression of immunoglobulins coinciding with reduced BCR diversity consistent with a restricted epitope-driven immune response. Analysis of DNA patterns from B-cells in basal-like and HER2-enriched BrCa showed a greater prevalence of BCR somatic hypermutation (SHM) suggestive of an antigen-restricted response (Iglesia et al, CCR 2014). Here, we studied the impact of this adaptive immune response on treatment response.
Methods: Using two neoadjuvant cooperative group trials in triple-negative (TNBC) and HER2-positive (HER2+) BrCa, we evaluated BCR diversity (as assessed by SHM diversity) as a continuous variable and as a binary variable (diverse/restricted) relative to BCR expression (the Restriction Index) in pre-treatment tumor samples from 265 patients with HER2+ BrCa treated on CALGB 40601, a randomized phase III trial of paclitaxel plus trastuzumab +/- lapatinib, and 443 patients with TNBC treated on CALGB 40603, a randomized phase II trial of standard chemotherapy +/- carboplatin and/or bevacizumab. We examined the relationship between a restricted immune response and pCR rate, the primary endpoint of both studies, overall and within molecular subtypes.
Results: In HER2+ BrCa, the combination of high immunoglobulin expression and lower sequence diversity (high Restriction Index) was observed in 28% of the pre-treatment biopsies, and varied by intrinsic subtype, with the greatest prevalence in the HER2-enriched subset (n=80, 46% vs 20% in all others). BCR restriction predicted improved pCR rates in all patients (67% versus 37%, p <0.0001). It remained significant in the HER2-enriched subset (n = 82, p=0.0086). The impact of Restriction Index on response to chemotherapy in TNBC is being analyzed and will be presented along with multivariate models to adjust for other patient and disease characteristics and explore potential interactions.
Conclusions: The presence of a restricted diversity B-cell response in HER2+ breast cancer correlates with improved response to neoadjuvant chemotherapy plus HER2-targeted therapy, which may in part explain its impact on prognosis. We will determine if a similar correlation exists with chemotherapy response in TNBC. This suggests that immunomodulatory therapies supporting a B-cell response may be a promising therapeutic approach to targeting these tumors.
Citation Format: Michael D Iglesia, Benjamin G Vincent, Jonathan S Serody, Lisa A Carey, William T Barry, William M Sikov, Clifford A Hudis, Eric M Winer, Charles M Perou. Impact of tumor-infiltrating B-cell clonal diversity on response to neoadjuvant therapy in triple negative and HER2+ breast cancer treated on CALGB (Alliance) 40601 and 40603 [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr PD1-2.
Collapse
|
84
|
Sikov WM, Barry WT, Hoadley KA, Pitcher BN, Singh B, Tolaney SM, Kuzma CS, Pluard TJ, Somlo G, Port ER, Golshan M, Berry DA, Hahn OM, Carey LA, Perou CM, Hudis CA, Winer EP. Abstract S4-05: Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) or bevacizumab (Bev): CALGB 40603/150709 (Allianc. Cancer Res 2015. [DOI: 10.1158/1538-7445.sabcs14-s4-05] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Adding either Cb or Bev to standard NACT significantly increases pCR rates in TNBC (Sikov et al, SABCS 2013). Genomic analysis may help us to identify determinants of response within this clinical phenotype.
Methods: Patients (pts) with clinical stage II-III TNBC received weekly paclitaxel x 12 followed by ddAC x 4 +/- Cb and/or Bev. Pre-treatment biopsies were collected in formalin, RNAlater and OCT; residual disease at surgery was biopsied when possible. Illumina mRNA sequencing (RNAseq) was performed. Gene expression values were normalized to a TCGA subset of clinically TNBC samples prior to downstream analysis. pCR was defined as the absence of residual invasive cancer in the breast (ypT0/is). For each molecular signature, prognostic (effect on pCR in the overall study population) and predictive (effect of the addition of Cb or Bev, separately, on pCR) relationships were explored with logistic regression models.
Results: PAM50 subtype analysis was performed on 367 pre-treatment samples (of 443 pts who started NACT); pCR results were available for 360, comprising the analysis subset. 87% of these displayed a basal-like gene expression pattern, 2% claudin-low, 4% HER2-enriched, <1% luminal A and 7% normal-like. In pts with basal-like tumors, pCRs rose from 47% to 61% with the addition of Cb (p=0.014), an increment which did not differ significantly from the overall study population (adding in the small number of non-basal-like tumors) (interaction p=0.93). In contrast, the addition of Bev increased pCRs in basal-like tumors from 45% to 64% (p=0.0009), while reducing pCRs in non-basal-likes from 60% to 43% (interaction p=0.024); thus, a basal-like gene expression pattern was predictive of benefit from Bev. Expression of a variety of immune signatures (B cell, T cell, IgG) was positively associated with pCR, but not predictive of increased benefit from either Cb or Bev. High expression of the HER2 amplicon signature was uncommon and not prognostic for pCR overall but was associated with reduced benefit from Cb (interaction p = 0.025). High proliferation, high p53 mutation and low IE (estrogen signaling) signatures were prognostic for higher pCR rates and predictive of benefit from Bev (interaction p=0.031, 0.0017, 0.0002, respectively). In basal-like pts with residual disease, surgical samples often (52%) displayed a normal-like PAM50 pattern, though this might be due to ‘contamination’ in low volume residual disease.
Conclusions: Selection criteria led to accrual of a high % of pts with basal-like tumors, limiting our ability to assess prognostic or predictive impact of intrinsic subtype on pCR. Given that limitation, the magnitude of pCR benefit with Cb was consistent across subtypes, while a basal-like pattern was predictive of greater pCR increment with Bev. Ongoing studies will test a large number of other gene signatures and biomarkers, including the Lehmann et al subtypes. Recognition of clinically relevant subpopulations within TNBC may distinguish pts likely to achieve a pCR from those for whom an investigational approach might be considered.
Citation Format: William M Sikov, William T Barry, Katherine A Hoadley, Brandelyn N Pitcher, Baljit Singh, Sara M Tolaney, Charles S Kuzma, Timothy J Pluard, George Somlo, Elisa R Port, Mehra Golshan, Donald A Berry, Olwen M Hahn, Lisa A Carey, Charles M Perou, Clifford A Hudis, Eric P Winer. Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) or bevacizumab (Bev): CALGB 40603/150709 (Allianc [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr S4-05.
Collapse
|
85
|
Hoadley KA, Barry WT, Pitcher BN, Parker JS, Wilkerson MD, Irvin W, Henry NL, Tolaney SM, Dang C, Krop IE, Berry DA, Mardis ER, Perou CM, Winer EP, Hudis CA, Carey LA. Abstract S3-06: Mutational analysis of CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer. Cancer Res 2015. [DOI: 10.1158/1538-7445.sabcs14-s3-06] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: In CALGB 40601, the HER2-Enriched (HER2-E) molecular subtype had significantly higher pathologic complete response (pCR) rates regardless of treatment arm (single HER2-targeting with T+L or T+H, dual targeting with T+H+L) (Carey et al, ASCO 2014). A TP53 mutation gene expression signature was significant in a multivariable analysis as were treatment, molecular subtype, proliferation, and an immune cell genomic signature. Mutational analysis is now available for this sample set.
Methods: 265 of 305 enrolled patients (pts) had RNA sequencing (RNAseq) of pre-treatment biospecimens; 181/265 had whole exome sequencing (WES) available from tumor and matched normal blood. Somatic mutations were detected by the program UNCeqR, which integrates WES and RNAseq. We examined the association of mutations with in-breast pCR, molecular subtypes, and gene expression signatures.
Results: In this subset, there were 57 HER2-E, 58 Luminal A, 51 Luminal B, 9 Basal-like, 4 Normal-like, and 2 Claudin-low. The pCR rate was 45% (51% THL, 47% TH and 34% TL), consistent with the entire study population. TP53 was the most frequently mutated gene (56%); frequency varied by molecular subtype (Fisher p<0.0001) with the highest in the HER2-E (88%). Type of mutation also varied by molecular subtype: 34% of TP53 mutations in HER2-E pts were nonsense or frame shift mutations compared to 20% in Luminal B and 11% in Luminal A. The presence of a TP53 mutation was significantly associated with achieving pCR (59% compared to 28% in wildtype; odds ratio=3.7, p<0.0001) which did not vary by treatment arm. TP53 mutation status by WES was strongly associated with a gene-expression based predictor (AUC=0.85, p<0.001), suggesting the RNAseq-based signature could be used as a surrogate measure of genotype. PIK3CA mutations were present in 36 pts (20%); 33/36 (92%) were in exons 9 and 20. PIK3CA mutations varied moderately among subtypes and were most prevalent in Luminal B (31%) and HER2-E (25%). Rates of pCR did not vary by PIK3CA mutation status (39% vs 47% in wildtype, p=0.46). GATA3 mutations were identified in 7 pts (4 Luminal A, 3 Luminal B), but only 1 pt achieved pCR. ERBB2 mutations were found in 7 pts: 2 HER2-E, 2 Luminal A, 3 Luminal B. Two were previously identified (the lapatinib-sensitive activating mutation V777L and the lapatinib-resistant mutation L755S), both were trastuzumab resistant in experimental models (Bose et al, Cancer Discovery 2013). Consistent with these results, the V777L pt achieved pCR on the THL arm; the L755S pt did not achieve pCR on the TL arm.
Conclusions: TP53 mutation is a frequent, clinically important event in HER2-positive disease and predicts pCR to chemotherapy plus HER2-targeting. Frequency and type of mutation was dependent on molecular subtype within this clinically HER2-positive cohort. Ongoing analyses are comparing WES data between pre- and post-treatment samples as well as investigating copy number and clonality. This research is supported in part by funds from GlaxoSmithKline and grants from the Breast Cancer Research Foundation.
Citation Format: Katherine A Hoadley, William T Barry, Brandelyn N Pitcher, Joel S Parker, Matthew D Wilkerson, William Irvin Jr, Norah Lynn Henry, Sara M Tolaney, Chau Dang, Ian E Krop, Donald A Berry, Elaine R Mardis, Charles M Perou, Eric P Winer, Clifford A Hudis, Lisa A Carey. Mutational analysis of CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr S3-06.
Collapse
|
86
|
Sagara Y, Barry WT, Vaz-Luis I, Aydogan F, Brock JE, Winer EP, Golshan M, Metzger-Filho O. Abstract P1-16-01: Effect of margin width on local recurrence in invasive lobular carcinoma treated with multimodality therapy. Cancer Res 2015. [DOI: 10.1158/1538-7445.sabcs14-p1-16-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Recent consensus guideline on margins for breast conserving surgery recommends the use of no ink on tumor as the standard for an adequate margin. Current recommendation extends to invasive lobular carcinoma (ILC), however the data in this subset is limited by small numbers. In the present analysis we sought to evaluate the influence of margin status on outcomes in ILC and mixed tumors.
Methods: We performed retrospective cohort study and reviewed 809 eligible patients diagnosed with ILC (337 with pure ILC; 472 with mixed ILC) with Stage I –III treated at Dana Farber/Brigham and Women’s Cancer Center (DFBWCC) between May 1997 and Dec 2007. Clinico-pathologic data was extracted following the Clinical Research Information Systems (CRIS) Database procedures and manually reviewed to confirm inclusion and details of margin status. Margin status was defined using the last ASCO/ASTRO/SSA consensus guidelines criteria. Analysis results were considered to be statistically significant when the two-tailed p-value was <0.05.
Results: Breast conservation was performed in 399 patients (49%). Margin status at the initial attempt for breast conservation was defined as follows: 180 (45%) negative, 64 (16%) positive, 71 (18%) ≤ 1mm margin, and 84 (21%) close margins (> 1 and < 3 mm). Following initial lumpectomy, 102 (25%) patients underwent additional surgery (96 re-excisions and 6 mastectomies) and residual invasive disease was found in 40 patients. Whole-breast radiation therapy was performed in 376 patients (96%). In multivariate models adjusted for classic clinico-pathologic factors, tumor size (HR= 1.8 95% CI 1.0 to 3.3, p=0.05), multifocality (HR= 2.0 95% CI 1.1 to 3.6, p= 0.02) and ILC subtype (HR= 2.0 95% CI 1.0 to 3.7, p=0.04) were correlated with positive margins, while year of diagnosis, age and pre-surgical MRI findings were not statistically significant.
With 72 months median follow-up, 12 ipsilateral breast cancers (3.1%), 5 other locoregional (1.2%) and 15 distant (3.8%) recurrences were observed after definitive breast conserving therapy. The incidence of locoregional recurrence (LRR) was 4.3% and similar for ILC and mixed ILC (p=0.76). In univariate analysis positive surgical margin was associated with LRR (HR=5.1, p= 0.03) and disease-free survival (DFS) (HR=8.9, p≤ .001), but due to limited number of cases and events this could not be adjusted for other clinico-pathologic prognostic factors in a mulitvariate model. Close surgical margins, margins within 1mm and multifocality were not associated with increased LRR or worse DFS. Re-excision did not impact on DFS for patients with close margin (p= 0.57) and within 1 mm margin (p= 0.85). By contrast, significant improvement of DFS following re-excision was observed in patients with positive margin (p= 0.01).
Conclusions: Following lumpectomy, local recurrence rates for ILC patients with close surgical margin and ≤ 1mm margin are low and equivalent to those in patients with negative margins. This study supports the validity of using no ink on tumor as the standard for an adequate margin for patients diagnosed with pure or mixed ILC treated with multimodality therapy.
Citation Format: Yasuaki Sagara, William T Barry, Ines Vaz-Luis, Fatih Aydogan, Jane E Brock, Eric P Winer, Mehra Golshan, Otto Metzger-Filho. Effect of margin width on local recurrence in invasive lobular carcinoma treated with multimodality therapy [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P1-16-01.
Collapse
|
87
|
Wagle N, Lin NU, Richardson AL, Leshchiner I, Mayer IA, Forero-Torres A, Hobday TJ, Dees EC, Nanda R, Rimawi MF, Guo H, Barry WT, Bose R, Shen W, Wolff AC, Gabriel SB, Garraway LA, Winer EP, Krop IE. Abstract PD3-5: Whole exome sequencing (WES) of HER2+ metastatic breast cancer (MBC) from patients with or without prior trastuzumab (T): A correlative analysis of TBCRC003. Cancer Res 2015. [DOI: 10.1158/1538-7445.sabcs14-pd3-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Although the spectrum of genomic alterations in primary, treatment-naïve breast tumors has been described, the genomic landscape of HER2+ MBC remains underexplored. Furthermore, tumor genomic alterations that arise after progression on anti-HER2 therapy are largely unknown.
Methods: We prospectively collected metastatic tumor biopsies from patients (pts) enrolled on TBCRC003 (NCT00470704), a phase II study evaluating the combination of lapatinib (L) and T in pts with HER2+ MBC who had varying degrees of prior T exposure. We performed WES on baseline metastatic biopsies and normal DNA from 57 pts. In 36 pts, we also performed WES on pre-treatment primary tumors. Tumors were analyzed for point mutations, insertions/deletions, and copy number alterations.
Results: Total accrual was 116 pts. 87 pts were registered in one of two efficacy cohorts: Cohort 1 included pts w no prior T for MBC. Pts with prior adjuvant T were included if the interval from last T to 1st recurrence > 12 months. Cohort 2 included pts with 1-2 prior lines of T for MBC or recurrence within 12 months of adjuvant T. An additional 29 pts were enrolled in a biomarker cohort (Cohort 3). Per-protocol efficacy analyses for 85 pts deemed evaluable are shown below:
Objective Response RateClinical Benefit RateMedian Time to ProgressionCohort 150% (90% CI 33.8-66.2%)57.5% (95% CI 40.9-73.0)7.4 monthsCohort 222.2% (90% CI 11.2-37.1%)42.2% (95% CI 27.7-57.8)5.3 months
As we previously reported (Wagle et al, ASCO 2014), across 57 metastatic tumors, significant recurrently mutated genes were TP53 (n=30; 53%) and PIK3CA (n=19; 33%). The frequency of mutant TP53 and PIK3CA was not significantly different from 119 primary, treatment-naïve HER2+ tumors sequenced in the TCGA study (50%, p=0.8 and 27%, p=0.5, respectively). Recurrent copy number alterations were also similar to TCGA data.
Comparing the 38 pts who received any prior T with the 19 pts who did not, there was no significant difference in the incidence of mutant TP53 (53% vs 53%, p=1.0) and PIK3CA (37% vs 26%, p=0.6).
We identified mutations in the HER2 kinase domain in 4/38 pts who received prior T (11%), as compared to 0/19 T-naïve pts. HER2 kinase domain mutations have been identified in ∼2% of HER2-negative cancers but <1% of primary HER2+ cancers. 3 of the mutations were L755S, which has been shown to be resistant to L and sensitive to irreversible HER2 inhibitors. The 4th mutation was D742N, a novel kinase domain mutation. None of the 4 pts with HER2 kinase domain mutations had an objective response, though 1 pt had stable disease for 29 weeks.
An analysis comparing paired archival primary tumors and baseline metastatic biopsies from 36 pts to identify genomic alterations acquired or enriched in the metastatic tumors will be presented.
Conclusions: We present an analysis of the genomic landscape of HER2+ MBC, including comparisons between matched primary tumors and metastatic biopsies. Somatic HER2 kinase mutations in pts with HER2+ MBC treated with prior T suggests that these mutations may be involved in resistance to T, and may predict poor response to additional anti-HER2 therapy with combined L and T. Novel therapeutic approaches may be required for these pts.
Citation Format: Nikhil Wagle, Nancy U Lin, Andrea L Richardson, Ignaty Leshchiner, Ingrid A Mayer, Andres Forero-Torres, Timothy J Hobday, Elizabeth C Dees, Rita Nanda, Mothaffar F Rimawi, Hao Guo, William T Barry, Ron Bose, Wei Shen, Antonio C Wolff, Stacey B Gabriel, Levi A Garraway, Eric P Winer, Ian E Krop. Whole exome sequencing (WES) of HER2+ metastatic breast cancer (MBC) from patients with or without prior trastuzumab (T): A correlative analysis of TBCRC003 [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr PD3-5.
Collapse
|
88
|
Sagara Y, Barry WT, Mallory MA, Vaz-Luis I, Aydogan F, Brock JE, Winer EP, Golshan M, Metzger-Filho O. Surgical Options and Locoregional Recurrence in Patients Diagnosed with Invasive Lobular Carcinoma of the Breast. Ann Surg Oncol 2015; 22:4280-6. [PMID: 25893416 DOI: 10.1245/s10434-015-4570-8] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2015] [Indexed: 11/18/2022]
Abstract
PURPOSE Recent consensus guidelines on margins for breast-conserving surgery (BCS) recommend the use of "no ink on tumor" as the standard for an adequate margin. The recommendations extend to invasive lobular carcinoma (ILC), but the data on this subset are limited. We reviewed our modern dataset on margin status with outcomes of ILC. METHODS We performed a retrospective cohort study on 736 patients with a diagnosis of stage I-III ILC treated at our cancer center between May 1997 and December 2007. Clinicopathologic data were extracted from the Clinical Research Information Systems Database. Margin status was defined using the latest ASCO/ASTRO/SSO consensus guideline criteria. RESULTS The initial surgery performed was mastectomy in 352 patients (48 %) and BCS in 384 patients (52 %). In multivariate analysis, tumor size and multifocality were significantly associated with high rates of mastectomy and positive surgical margins at initial BCS. After initial BCS, additional surgery was performed in 92 patients (24 %). During a 72-month median follow-up period, 12 (3.1 %) ipsilateral breast tumor recurrences (IBTR) and 5 (1.3 %) other locoregional recurrences (LRR) were observed. Patients with margins with ink on tumor who did not receive further surgery were found to have significantly increased LRR [odds ratio (OR) 5.5; p = 0.02] and IBTR (OR 8.5; p = 0.006), whereas patients with close margins (1-3 mm) and margins within 1 mm were not. CONCLUSIONS Our study supports the validity of using "no ink on tumor" as the standard for a negative margin for pure and mixed ILC treated with multimodality therapy.
Collapse
|
89
|
Horton JK, Blitzblau RC, Yoo S, Geradts J, Chang Z, Baker JA, Georgiade GS, Chen W, Siamakpour-Reihani S, Wang C, Broadwater G, Groth J, Palta M, Dewhirst M, Barry WT, Duffy EA, Chi JTA, Hwang ES. Preoperative Single-Fraction Partial Breast Radiation Therapy: A Novel Phase 1, Dose-Escalation Protocol With Radiation Response Biomarkers. Int J Radiat Oncol Biol Phys 2015; 92:846-55. [PMID: 26104938 DOI: 10.1016/j.ijrobp.2015.03.007] [Citation(s) in RCA: 93] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2015] [Revised: 02/22/2015] [Accepted: 03/09/2015] [Indexed: 10/23/2022]
Abstract
PURPOSE Women with biologically favorable early-stage breast cancer are increasingly treated with accelerated partial breast radiation (PBI). However, treatment-related morbidities have been linked to the large postoperative treatment volumes required for external beam PBI. Relative to external beam delivery, alternative PBI techniques require equipment that is not universally available. To address these issues, we designed a phase 1 trial utilizing widely available technology to 1) evaluate the safety of a single radiation treatment delivered preoperatively to the small-volume, intact breast tumor and 2) identify imaging and genomic markers of radiation response. METHODS AND MATERIALS Women aged ≥55 years with clinically node-negative, estrogen receptor-positive, and/or progesterone receptor-positive HER2-, T1 invasive carcinomas, or low- to intermediate-grade in situ disease ≤2 cm were enrolled (n=32). Intensity modulated radiation therapy was used to deliver 15 Gy (n=8), 18 Gy (n=8), or 21 Gy (n=16) to the tumor with a 1.5-cm margin. Lumpectomy was performed within 10 days. Paired pre- and postradiation magnetic resonance images and patient tumor samples were analyzed. RESULTS No dose-limiting toxicity was observed. At a median follow-up of 23 months, there have been no recurrences. Physician-rated cosmetic outcomes were good/excellent, and chronic toxicities were grade 1 to 2 (fibrosis, hyperpigmentation) in patients receiving preoperative radiation only. Evidence of dose-dependent changes in vascular permeability, cell density, and expression of genes regulating immunity and cell death were seen in response to radiation. CONCLUSIONS Preoperative single-dose radiation therapy to intact breast tumors is well tolerated. Radiation response is marked by early indicators of cell death in this biologically favorable patient cohort. This study represents a first step toward a novel partial breast radiation approach. Preoperative radiation should be tested in future clinical trials because it has the potential to challenge the current treatment paradigm and provide a path forward to identify radiation response biomarkers.
Collapse
|
90
|
Greaney ML, Sprunck-Harrild K, Ruddy KJ, Ligibel J, Barry WT, Baker E, Meyer M, Emmons KM, Partridge AH. Study protocol for Young & Strong: a cluster randomized design to increase attention to unique issues faced by young women with newly diagnosed breast cancer. BMC Public Health 2015; 15:37. [PMID: 25636332 PMCID: PMC4328063 DOI: 10.1186/s12889-015-1346-9] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2014] [Accepted: 01/02/2015] [Indexed: 12/27/2022] Open
Abstract
Background Each year, approximately 11% of women diagnosed with breast cancer in the United States are 45 years of age or younger. These women have concerns specific to or accentuated by their age, including fertility-related concerns, and have higher rates of psychosocial distress than women diagnosed at older ages. Current guidelines recommend that fertility risks be considered early in all treatment plans; however, the extant research indicates that attention to fertility by the healthcare team is limited. Importantly, attention to fertility may be a proxy for whether or not other important issues warranting attention in younger women with breast cancer are addressed, including genetic risks, psychosocial distress, sexual functioning, and body image concerns. The Young & Strong study tests the efficacy of an intervention designed for young women recently diagnosed with breast cancer and their oncologists with the intention to: 1) increase attention to fertility as an important surrogate for other issues facing young women, 2) educate and support young women and their providers, and 3) reduce psychosocial distress among young women with breast cancer. Methods/Design The study employs a cluster randomized design including 14 academic institutions and 40 community sites across the U.S. assigned to either the study intervention arm or contact-time comparison intervention arm. Academic institutions enroll up to 15 patients per site while community sites enroll up to 10 patients. Patient eligibility requirements include: an initial diagnosis of stage I-III invasive breast cancer within three months prior, without a known recurrence or metastatic breast cancer; 18–45 years of age at diagnosis; ability to read and write in English. The primary outcome is oncologists’ attention to fertility concerns as determined by medical record review. Secondary outcomes include differences in patient satisfaction with care and psychosocial distress between the two study arms. Discussion Study findings will provide valuable insight into how to increase attention to fertility and other issues specific to young women with breast cancer and how to improve doctor-patient communication around these issues, which may promote better quality of care for this population. Trial registration NCT01647607. Registered July 19, 2012.
Collapse
|
91
|
Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis M, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Partridge AH, Guo H, Hudis CA, Krop IE, Burstein HJ, Winer EP. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med 2015; 372:134-41. [PMID: 25564897 PMCID: PMC4313867 DOI: 10.1056/nejmoa1406281] [Citation(s) in RCA: 484] [Impact Index Per Article: 53.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
BACKGROUND No single standard treatment exists for patients with small, node-negative, human epidermal growth factor receptor type 2 (HER2)-positive breast cancers, because most of these patients have been ineligible for the pivotal trials of adjuvant trastuzumab. METHODS We performed an uncontrolled, single-group, multicenter, investigator-initiated study of adjuvant paclitaxel and trastuzumab in 406 patients with tumors measuring up to 3 cm in greatest dimension. Patients received weekly treatment with paclitaxel and trastuzumab for 12 weeks, followed by 9 months of trastuzumab monotherapy. The primary end point was survival free from invasive disease. RESULTS The median follow-up period was 4.0 years. The 3-year rate of survival free from invasive disease was 98.7% (95% confidence interval [CI], 97.6 to 99.8). Among the 12 relapses seen, 2 were due to distant metastatic breast cancer. Excluding contralateral HER2-negative breast cancers and nonbreast cancers, 7 disease-specific events were noted. A total of 13 patients (3.2%; 95% CI, 1.7 to 5.4) reported at least one episode of grade 3 neuropathy, and 2 had symptomatic congestive heart failure (0.5%; 95% CI, 0.1 to 1.8), both of whom had normalization of the left ventricular ejection fraction after discontinuation of trastuzumab. A total of 13 patients had significant asymptomatic declines in ejection fraction (3.2%; 95% CI, 1.7 to 5.4), as defined by the study, but 11 of these patients were able to resume trastuzumab therapy after a brief interruption. CONCLUSIONS Among women with predominantly stage I HER2-positive breast cancer, treatment with adjuvant paclitaxel plus trastuzumab was associated with a risk of early recurrence of about 2%; 6% of patients withdrew from the study because of protocol-specified adverse events. (Funded by Genentech; ClinicalTrials.gov number, NCT00542451.).
Collapse
MESH Headings
- Adenocarcinoma/chemistry
- Adenocarcinoma/drug therapy
- Adenocarcinoma/mortality
- Adenocarcinoma/therapy
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal, Humanized/administration & dosage
- Antibodies, Monoclonal, Humanized/adverse effects
- Antineoplastic Combined Chemotherapy Protocols/adverse effects
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Breast Neoplasms/chemistry
- Breast Neoplasms/drug therapy
- Breast Neoplasms/mortality
- Breast Neoplasms/therapy
- Chemotherapy, Adjuvant
- Disease-Free Survival
- Female
- Follow-Up Studies
- Humans
- Infusions, Intravenous
- Mastectomy, Segmental
- Middle Aged
- Neoplasm Recurrence, Local
- Paclitaxel/administration & dosage
- Paclitaxel/adverse effects
- Radiotherapy
- Receptor, ErbB-2/analysis
- Receptor, ErbB-2/immunology
- Survival Rate
- Trastuzumab
Collapse
|
92
|
Burstein HJ, Cirrincione CT, Barry WT, Chew HK, Tolaney SM, Lake DE, Ma C, Blackwell KL, Winer EP, Hudis CA. Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer-CALGB 40302 (Alliance). J Clin Oncol 2014; 32:3959-66. [PMID: 25348000 DOI: 10.1200/jco.2014.56.7941] [Citation(s) in RCA: 65] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
Abstract
PURPOSE CALGB 40302 sought to determine whether lapatinib would improve progression-free survival (PFS) among women with hormone receptor-positive metastatic breast cancer treated with fulvestrant. PATIENTS AND METHODS Eligible women had estrogen receptor-positive and/or progesterone receptor-positive tumors, regardless of human epidermal growth factor receptor 2 (HER2) status, and prior aromatase inhibitor treatment. Patients received fulvestrant 500 mg intramuscularly on day 1, followed by 250 mg on days 15 and 28 and every 4 weeks thereafter, and either lapatinib 1,500 mg or placebo daily. The study planned to accrue 324 patients and was powered for a 50% improvement in PFS with lapatinib from 5 to 7.5 months. RESULTS At the third planned interim analysis, the futility boundary was crossed, and the data and safety monitoring board recommend study closure, having accrued 295 patients. At the final analysis, there was no difference in PFS (hazard ratio [HR] of placebo to lapatinib, 1.04; 95% CI, 0.82 to 1.33; P = .37); median PFS was 4.7 months for fulvestrant plus lapatinib versus 3.8 months for fulvestrant plus placebo. There was no difference in overall survival (OS) (HR, 0.91; 95% CI, 0.68 to 1.21; P = .25). For HER2-normal tumors, median PFS did not differ by treatment arm (4.1 v 3.8 months). For HER2-positive tumors, lapatinib was associated with longer median PFS (5.9 v 3.3 months), but the differential treatment effect by HER2 status was not significant (P = .53). The most frequent toxicities were diarrhea, fatigue, and rash associated with lapatinib. CONCLUSION Adding lapatinib to fulvestrant does not improve PFS or OS in advanced ER-positive breast cancer and is more toxic.
Collapse
|
93
|
Meltzer EB, Barry WT, Yang IV, Brown KK, Schwarz MI, Patel H, Ashley A, Noble PW, Schwartz DA, Steele MP. Familial and sporadic idiopathic pulmonary fibrosis: making the diagnosis from peripheral blood. BMC Genomics 2014; 15:902. [PMID: 25318837 PMCID: PMC4288625 DOI: 10.1186/1471-2164-15-902] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2014] [Accepted: 07/10/2014] [Indexed: 12/26/2022] Open
Abstract
Background Peripheral blood biomarkers might improve diagnostic accuracy for idiopathic pulmonary fibrosis (IPF). Results Gene expression profiles were obtained from 89 patients with IPF and 26 normal controls. Samples were stratified according to severity of disease based on pulmonary function. The stratified dataset was split into subsets; two-thirds of the samples were selected to comprise the training set, while one-third was reserved for the validation set. Bayesian probit regression was used on the training set to develop a gene expression model for IPF versus normal. The gene expression model was tested by using it on the validation set to perform class prediction. Unsupervised clustering failed to discriminate between samples of different severity. Therefore, samples of all severities were included in the training and validation sets, in equal proportions. A gene signature model was developed from the training set. The model was built in an iterative fashion with the number of gene features selected to minimize the misclassification error in cross validation. The final model was based on the top 108 discriminating genes in the training set. The signature was successfully applied to the validation set, ROC area under the curve = 0.893, p < 0.0001. Using the optimal threshold (0.74) accurate class predictions were made for 77% of the test cases with sensitivity = 0.70, specificity = 1.00. Conclusions By using Bayesian probit regression to develop a model, we show that it is entirely possible to make a diagnosis of IPF from the peripheral blood with gene signatures. Electronic supplementary material The online version of this article (doi:10.1186/1471-2164-15-902) contains supplementary material, which is available to authorized users.
Collapse
|
94
|
Prat A, Lluch A, Albanell J, Barry WT, Fan C, Chacón JI, Parker JS, Calvo L, Plazaola A, Arcusa A, Seguí-Palmer MA, Burgues O, Ribelles N, Rodriguez-Lescure A, Guerrero A, Ruiz-Borrego M, Munarriz B, López JA, Adamo B, Cheang MCU, Li Y, Hu Z, Gulley ML, Vidal MJ, Pitcher BN, Liu MC, Citron ML, Ellis MJ, Mardis E, Vickery T, Hudis CA, Winer EP, Carey LA, Caballero R, Carrasco E, Martín M, Perou CM, Alba E. Predicting response and survival in chemotherapy-treated triple-negative breast cancer. Br J Cancer 2014; 111:1532-41. [PMID: 25101563 PMCID: PMC4200088 DOI: 10.1038/bjc.2014.444] [Citation(s) in RCA: 77] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2014] [Revised: 06/26/2014] [Accepted: 07/13/2014] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND In this study, we evaluated the ability of gene expression profiles to predict chemotherapy response and survival in triple-negative breast cancer (TNBC). METHODS Gene expression and clinical-pathological data were evaluated in five independent cohorts, including three randomised clinical trials for a total of 1055 patients with TNBC, basal-like disease (BLBC) or both. Previously defined intrinsic molecular subtype and a proliferation signature were determined and tested. Each signature was tested using multivariable logistic regression models (for pCR (pathological complete response)) and Cox models (for survival). Within TNBC, interactions between each signature and the basal-like subtype (vs other subtypes) for predicting either pCR or survival were investigated. RESULTS Within TNBC, all intrinsic subtypes were identified but BLBC predominated (55-81%). Significant associations between genomic signatures and response and survival after chemotherapy were only identified within BLBC and not within TNBC as a whole. In particular, high expression of a previously identified proliferation signature, or low expression of the luminal A signature, was found independently associated with pCR and improved survival following chemotherapy across different cohorts. Significant interaction tests were only obtained between each signature and the BLBC subtype for prediction of chemotherapy response or survival. CONCLUSIONS The proliferation signature predicts response and improved survival after chemotherapy, but only within BLBC. This highlights the clinical implications of TNBC heterogeneity, and suggests that future clinical trials focused on this phenotypic subtype should consider stratifying patients as having BLBC or not.
Collapse
|
95
|
Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, Rimel B, Buss MK, Nattam S, Hurteau J, Luo W, Quy P, Whalen C, Obermayer L, Lee H, Winer EP, Kohn EC, Ivy SP, Matulonis UA. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol 2014; 15:1207-14. [PMID: 25218906 PMCID: PMC4294183 DOI: 10.1016/s1470-2045(14)70391-2] [Citation(s) in RCA: 447] [Impact Index Per Article: 44.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Abstract
BACKGROUND Olaparib is a poly(ADP-ribose) polymerase inhibitor and cediranib is an anti-angiogenic agent with activity against VEGF receptor (VEGFR) 1, VEGFR2, and VEGFR3. Both oral agents have antitumour activity in women with recurrent ovarian cancer, and their combination was active and had manageable toxicities in a phase 1 trial. We investigated whether this combination could improve progression-free survival (PFS) compared with olaparib monotherapy in women with recurrent platinum-sensitive ovarian cancer. METHODS In our randomised, open-label, phase 2 study, we recruited women (aged ≥18 years) who had measurable platinum-sensitive, relapsed, high-grade serous or endometrioid ovarian, fallopian tube, or primary peritoneal cancer, or those with deleterious germline BRCA1/2 mutations from nine participating US academic medical centres. We randomly allocated participants (1:1) according to permuted blocks, stratified by germline BRCA status and previous anti-angiogenic therapy, to receive olaparib capsules 400 mg twice daily or the combination at the recommended phase 2 dose of cediranib 30 mg daily and olaparib capsules 200 mg twice daily. The primary endpoint was progression-free survival analysed in the intention-to-treat population. The phase 2 trial is no longer accruing patients. An interim analysis was conducted in November, 2013, after 50% of expected events had occurred and efficacy results were unmasked. The primary analysis was performed on March 31, 2014, after 47 events (66% of those expected). The trial is registered with ClinicalTrials.gov, number NCT01116648. FINDINGS Between Oct 26, 2011, and June 3, 2013, we randomly allocated 46 women to receive olaparib alone and 44 to receive the combination of olaparib and cediranib. Median PFS was 17·7 months (95% CI 14·7-not reached) for the women treated with cediranib plus olaparib compared with 9·0 months (95% CI 5·7-16·5) for those treated with olaparib monotherapy (hazard ratio 0·42, 95% CI 0·23-0·76; p=0·005). Grade 3 and 4 adverse events were more common with combination therapy than with monotherapy, including fatigue (12 patients in the cediranib plus olaparib group vs five patients in the olaparib monotherapy group), diarrhoea (ten vs none), and hypertension (18 vs none). INTERPRETATION Cediranib plus olaparib seems to improve PFS in women with recurrent platinum-sensitive high-grade serous or endometrioid ovarian cancer, and warrants study in a phase 3 trial. The side-effect profile suggests such investigations should include assessments of quality of life and patient-reported outcomes to understand the effects of a continuing oral regimen with that of intermittent chemotherapy. FUNDING American Recovery and Reinvestment Act grant from the National Institutes of Health (NIH) (3 U01 CA062490-16S2); Intramural Program of the Center for Cancer Research; and the Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH.
Collapse
|
96
|
Myers A, Barry WT, Hirsch MS, Matulonis U, Lee L. β-Catenin mutations in recurrent FIGO IA grade I endometrioid endometrial cancers. Gynecol Oncol 2014; 134:426-7. [PMID: 24952365 DOI: 10.1016/j.ygyno.2014.06.010] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2014] [Revised: 06/06/2014] [Accepted: 06/11/2014] [Indexed: 11/29/2022]
|
97
|
Sheppard VB, Faul LA, Luta G, Clapp JD, Yung RL, Wang JHY, Kimmick G, Isaacs C, Tallarico M, Barry WT, Pitcher BN, Hudis C, Winer EP, Cohen HJ, Muss HB, Hurria A, Mandelblatt JS. Frailty and adherence to adjuvant hormonal therapy in older women with breast cancer: CALGB protocol 369901. J Clin Oncol 2014; 32:2318-27. [PMID: 24934786 DOI: 10.1200/jco.2013.51.7367] [Citation(s) in RCA: 68] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
PURPOSE Most patients with breast cancer age ≥ 65 years (ie, older patients) are eligible for adjuvant hormonal therapy, but use is not universal. We examined the influence of frailty on hormonal therapy noninitiation and discontinuation. PATIENTS AND METHODS A prospective cohort of 1,288 older women diagnosed with invasive, nonmetastatic breast cancer recruited from 78 sites from 2004 to 2011 were included (1,062 had estrogen receptor-positive tumors). Interviews were conducted at baseline, 6 months, and annually for up to 7 years to collect sociodemographic, health care, and psychosocial data. Hormonal initiation was defined from records and discontinuation from self-report. Baseline frailty was measured using a previously validated 35-item scale and grouped as prefrail or frail versus robust. Logistic regression and proportional hazards models were used to assess factors associated with noninitiation and discontinuation, respectively. RESULTS Most women (76.4%) were robust. Noninitiation of hormonal therapy was low (14%), but in prefrail or frail (v robust) women the odds of noninitiation were 1.63 times as high (95% CI, 1.11 to 2.40; P = .013) after covariate adjustment. Nonwhites (v whites) had higher odds of noninitiation (odds ratio, 1.71; 95% CI, 1.04 to 2.80; P = .033) after covariate adjustment. Among initiators, the 5-year continuation probability was 48.5%. After adjustment, the risk of discontinuation was higher with increasing age (P = .005) and lower for stage ≥ IIB (v stage I) disease (P = .003). CONCLUSION Frailty is associated with noninitiation of hormonal therapy, but it does not seem to be a major predictor of early discontinuation in older patients.
Collapse
|
98
|
Faul LA, Luta G, Sheppard V, Isaacs C, Cohen HJ, Muss HB, Yung R, Clapp JD, Winer E, Hudis C, Tallarico M, Wang J, Barry WT, Mandelblatt JS. Associations among survivorship care plans, experiences of survivorship care, and functioning in older breast cancer survivors: CALGB/Alliance 369901. J Cancer Surviv 2014; 8:627-37. [PMID: 24917307 DOI: 10.1007/s11764-014-0371-5] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2014] [Accepted: 05/19/2014] [Indexed: 11/12/2022]
Abstract
PURPOSE Survivorship care plans (SCP) are recommended for all cancer patients and could be especially useful to survivors 65 years and over ("older"). This study examined receipt of SCPs among older breast cancer survivors and whether SCPs were associated with improved patient-reported outcomes. METHODS Three hundred and twenty-eight older women diagnosed with invasive, nonmetastatic breast cancer between 2007-2011 were recruited from 78 cooperative-group sites. Participants completed telephone interviews at baseline and 1-year posttreatment. Regression analyses examined SCP receipt (yes/no) and functioning (EORTC-QLQ-C30), cancer worry, and experiences of survivorship care (care coordination, knowledge). RESULTS Only 35% of women received SCPs. For each 1-year increase in age, there was a 5% lower odds of receiving an SCP (odds ratio (OR) = 0.94, 95% confidence interval (CI) 0.91-0.98, p = 0.007). Besides age, no other factor predicted SCPs. SCP receipt was associated with greater knowledge and understanding of requisite follow-up care (p < 0.05); however, functioning was not significantly different among those with vs. without SCPs. CONCLUSIONS Receipt of care plans was limited. SCPs improved understanding of breast cancer follow-up care among older survivors, but did not impact functioning one year post-treatment. IMPLICATIONS FOR CANCER SURVIVORS To impact functioning and salient needs of the growing cohort of older survivors, survivorship care plans likely should be tailored to geriatric-specific issues. To improve functioning, SCP content should expand to include exercise, nutrition, polypharmacy, social support and management of symptom burden from cancer, and other comorbid conditions. To improve follow-up care for cancer survivors, SCPs should delineate shared care roles between oncology and primary care in managing recurrence surveillance, screening, and cancer sequelae.
Collapse
|
99
|
Stevenson M, Christensen J, Shoemaker D, Foster T, Barry WT, Tong BC, Wahidi M, Shofer S, Datto M, Ginsburg G, Crawford J, D'Amico T, Ready N. Tumor acquisition for biomarker research in lung cancer. Cancer Invest 2014; 32:291-8. [PMID: 24810245 DOI: 10.3109/07357907.2014.911880] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Abstract
The biopsy collection data from two lung cancer trials that required fresh tumor samples be obtained for microarray analysis were reviewed. In the trial for advanced disease, microarray data were obtained on 50 patient samples, giving an overall success rate of 60.2%. The majority of the specimens were obtained through CT-guided lung biopsies (N = 30). In the trial for early-stage patients, 28 tissue specimens were collected from excess tumor after surgical resection with a success rate of 85.7%. This tissue procurement program documents the feasibility in obtaining fresh tumor specimens prospectively that could be used for molecular testing.
Collapse
|
100
|
Haga SB, Barry WT, Mills R, Svetkey L, Suchindran S, Willard HF, Ginsburg GS. Impact of delivery models on understanding genomic risk for type 2 diabetes. Public Health Genomics 2014; 17:95-104. [PMID: 24577154 DOI: 10.1159/000358413] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2013] [Accepted: 12/19/2013] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND Genetic information, typically communicated in-person by genetic counselors, can be challenging to comprehend; delivery of this information online--as is becoming more common--has the potential of increasing these challenges. METHODS To address the impact of the mode of delivery of genomic risk information, 300 individuals were recruited from the general public and randomized to receive genomic risk information for type 2 diabetes mellitus in-person from a board-certified genetic counselor or online through the testing company's website. RESULTS Participants were asked to indicate their genomic risk and overall lifetime risk as reported on their test report as well as to interpret their genomic risk (increased, decreased, or same as population). For each question, 59% of participants correctly indicated their risk. Participants who received their results in-person were more likely than those who reviewed their results on-line to correctly interpret their genomic risk (72 vs. 47%, p = 0.0002) and report their actual genomic risk (69 vs. 49%, p = 0.002). CONCLUSIONS The delivery of personal genomic risk through a trained health professional resulted in significantly higher comprehension. Therefore, if the online delivery of genomic test results is to become more widespread, further evaluation of this method of communication may be needed to ensure the effective presentation of results to promote comprehension.
Collapse
|